Pfizer and Astellas presented new data at the European Society for Medical Oncology (ESMO) 2026 congress on PADCEV (enfortumab vedotin) plus pembrolizumab for advanced bladder cancer. The findings highlighted a durable survival benefit with the combination therapy.
Updated exploratory analyses from the Phase 3 EV-302 and EV-303 trials support the regimen as a foundational first-line treatment for previously untreated locally advanced or metastatic urothelial carcinoma. The data also support the combination as a potential new standard of care in the perioperative setting for muscle-invasive bladder cancer.
The results support Pfizer’s strategy to expand its oncology portfolio. They may be especially relevant to patients who have had limited effective treatment options, including those ineligible for cisplatin-based chemotherapy.